CAPON-nNOS coupling can serve as a target for developing new anxiolytics

Nature Medicine

Volumn 20, Issue 9, 2014, Pages 1050-1054

  Zhu, Li Juan ^a   Li, Ting You ^a   Luo, Chun Xia ^a   Jiang, Nan ^a   Chang, Lei ^a   Lin, Yu Hui ^a   Zhou, Hai Hui ^a   Chen, Chen ^a   Zhang, Yu ^a   Lu, Wei ^a,c   Gao, Li Yan ^a   Ma, Yu ^a   Zhou, Qi Gang ^a   Hu, Qin ^a   Hu, Xiao Ling ^b   Zhang, Jing ^a   Wu, Hai Yin ^a   Zhu, Dong Ya ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Ctr of Drug Metab and Pharmacokin   (China)

^c SOUTHEAST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; NEURONAL NITRIC OXIDE SYNTHASE; NOS1AP PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ARTICLE; HUMAN; METABOLISM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTI-ANXIETY AGENTS; HUMANS; NITRIC OXIDE SYNTHASE TYPE I;

EID: 84908323980     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3644     Document Type: Article

References (42)

1. Kessler, R.C. et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62, 593-602 (2005).
2. Tye, K.M. et al. Amygdala circuitry mediating reversible and bidirectional control of anxiety. Nature 471, 358-362 (2011).
3. Rupprecht, R. et al. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science 325, 490-493 (2009).
4. Zhou, Q.G. et al. Hippocampal neuronal nitric oxide synthase mediates the stress-related depressive behaviors of glucocorticoids by downregulating glucocorticoid receptor. J. Neurosci. 31, 7579-7590 (2011).
5. Reif, A. et al. A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function. Mol. Psychiatry 11, 286-300 (2006).
6. Nelson, R.J. et al. Behavioural abnormalities in male mice lacking neuronal nitric oxide synthase. Nature 378, 383-386 (1995).
7. Zhang, J. et al. Neuronal nitric oxide synthase alteration accounts for the role of 5-HT1A-receptor in modulating anxiety-related behaviors. J. Neurosci. 30, 2433-2441 (2010).
8. Fang, M. et al. Dexras1: a G protein specifically coupled to neuronal nitric oxide synthase via CAPON. Neuron 28, 183-193 (2000).
9. Zhou, L. et al. Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95. Nat. Med. 16, 1439-1443 (2010).
10. Jaffrey, S.R., Snowman, A.M., Eliasson, M.J., Cohen, N.A., Snyder, S.H. CAPON: a protein associated with neuronal nitric oxide synthase that regulates its interactions with PSD95. Neuron 20, 115-124 (1998).
11. Carrel, D. et al. NOS1AP regulates dendrite patterning of hippocampal neurons through a carboxypeptidase E-mediated pathway. J. Neurosci. 29, 8248-8258 (2009).
12. Richier, L. et al. NOS1AP associates with Scribble and regulates dendritic spine development. J. Neurosci. 30, 4796-4805 (2010).
13. Lawford, B.R. et al. NOS1AP is associated with increased severity of PTSD and depression in untreated combat veterans. J. Affect. Disord. 147, 87-93 (2013).
14. Cheng, H.Y. et al. The molecular gatekeeper Dexras1 sculpts the photic responsiveness of the mammalian circadian clock. J. Neurosci. 26, 12984-12995 (2006).
15. Mogha, A., Guariglia, S.R., Debata, P.R., Wen, G.Y., Banerjee, P. Serotonin 1A receptor-mediated signaling through ERK and PKC? is essential for normal synaptogenesis in neonatal mouse hippocampus. Transl. Psychiatry 2, e66 (2012).
16. Giachello, C.N. et al. MAPK/Erk-dependent phosphorylation of synapsin mediates formation of functional synapses and short-term homosynaptic plasticity. J. Cell Sci. 123, 881-893 (2010).
17. Duman, R.S., Aghajanian, G.K. Synaptic dysfunction in depression: potential therapeutic targets. Science 338, 68-72 (2012).
18. Duric, V. et al. A negative regulator of MAP kinase causes depressive behavior. Nat. Med. 16, 1328-1332 (2010).
19. Xu, B. et al. Increased expression in dorsolateral prefrontal cortex of CAPON in schizophrenia and bipolar disorder. PLoS Med. 2, e263 (2005).
20. Brzustowicz, L.M. NOS1AP in schizophrenia. Curr. Psychiatry Rep. 10, 158-163 (2008).
21. Tochio, H., Zhang, Q., Mandal, P., Li, M., Zhang, M. Solution structure of the extended neuronal nitric oxide synthase PDZ domain complexed with an associated peptide. Nat. Struct. Biol. 6, 417-421 (1999).
22. Schwarze, S.R., Ho, A., Vocero-Akbani, A., Dowdy, S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285, 1569-1572 (1999).
23. Martinowich, K., Manji, H., Lu, B. Mew insights into BDNF function in depression and anxiety. Nat. Neurosci. 10, 1089-1093 (2007).
24. Parihar, V.K., Hattiangady, B., Kuruba, R., Shuai, B., Shetty, A.K. Predictable chronic mild stress improves mood, hippocampal neurogenesis and memory. Mol. Psychiatry 16, 171-183 (2011).
25. Pucilowska, J., Puzerey, P.A., Karlo, J.C., Galán, R.F., Landreth, G.E. Disrupted ERK signaling during cortical development leads to abnormal progenitor proliferation, neuronal and network excitability and behavior, modeling human neuron-cardio-facial-cutaneous and related syndromes. J. Neurosci. 32, 8663-8677 (2012).
26. Hu, Y. et al. Hippocampal nitric oxide contributes to sex difference in affective behaviors. Proc. Natl. Acad. Sci. USA 109, 14224-14229 (2012).
27. Soetanto, A. et al. Association of anxiety and depression with microtubule-associated protein 2-and synaptopodin-immunolabeleddendrite and spine densities in hippocampal CA3 of older humans. Arch. Gen. Psychiatry 67, 448-457 (2010).
28. Mucha, M. et al. Lipocalin-2 controls neuronal excitability and anxiety by regulating dendrtitic spine formation and maturation. Proc. Natl. Acad. Sci. USA 108, 18436-18441 (2011).
29. Lonetti, G. et al. Early environmental enrichment moderates the behavioral and synaptic phenotype of MeCP2 null mice. Biol. Psychiatry 67, 657-665 (2010).
30. Kao, H.T. et al. A third member of the synapsin gene family. Proc. Natl. Acad. Sci. USA 95, 4667-4672 (1998).
31. Ryan, X.P. et al. The Rho-specific GEF Lfc interacts with neurabin and spinophilin to regulate dendritic spine morphology. Neuron 47, 85-100 (2005).
32. Xu, J.Y., Sastry, B.R. Benzodiazepine involvement in LTP of the GABA-ergic IPSC in rat hippocampal CA1 neurons. Brain Res. 1062, 134-143 (2005).
33. Feyder, M. et al. Association of mouse Dlg4 (PSD-95) gene deletion and human DLG4 gene variation with phenotypes relevant to autism spectrum disorders and Williams' syndrome. Am. J. Psychiatry 167, 1508-1517 (2010).
34. Jaffrey, S.R., Benfenati, F., Snowman, A.M., Czernik, A.J., Snyder, S.H. Neuronal nitric-oxide synthase localization mediated by a ternary complex with synapsin and CAPON. Proc. Natl. Acad. Sci. USA 99, 3199-3204 (2002).
35. Chang, K.C. et al. CAPON modulates cardiac repolarization via neuronal nitric oxide synthase signaling in the heart. Proc. Natl. Acad. Sci. USA 105, 4477-4482 (2008).
36. Munoz, J.R., Stoutenger, B.R., Robinson, A.P., Spees, J.L., Prockop, D.J. Human stem progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice. Proc. Natl. Acad. Sci. USA 102, 18171-18176 (2005).
37. Fanselow, M.S., Dong, H.W. Are the dorsal and ventral hippocampus functionally distinct structures? Neuron 65, 7-19 (2010).
38. Rudolph, U. et al. Benzodiazepine actions mediated by specific ?-aminobutyric acidA receptor subtypes. Nature 401, 796-800 (1999).
39. Bonetti, E.P. et al. Benzodiazepine antagonist RO 15-1788: neurological and behavioral effects. Psychopharmacology (Berl.) 78, 8-18 (1982).
40. Ren, L. et al. GABAA receptor subtype selectivity underlying anxiolytic effect of 6-hydroxyflavone. Biochem. Pharmacol. 79, 1337-1344 (2010).
41. Stricker, N.L. et al. PDZ domain of neuronal nitric oxide synthase recognizes novel C-terminal peptide sequences. Nat. Biotechnol. 15, 336-342 (1997).
42. Doyle, D.A. et al. Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ. Cell 85, 1067-1076 (1996).